Table 4.

Network meta-analyses for any grade AEs.

Atezolizumab + Bevacizumab
1.69 (0.11, 26.75)	Brivanib
0.23 (0.01, 7.02)	0.14 (0.01, 3.37)	Donafenib
0.69 (0.05, 9.05)	0.41 (0.04, 4.23)	2.96 (0.14, 59.14)	Erlotinib + Sorafenib
0.68 (0.05, 9.12)	0.40 (0.04, 4.15)	2.92 (0.14, 58.84)	0.99 (0.11, 8.51)	GEMOX + Sorafenib
1.42 (0.08, 25.51)	0.83 (0.06, 12.03)	6.01 (0.22, 164.01)	2.04 (0.17, 24.01)	2.07 (0.17, 24.36)	Lenvatinib
0.17 (0.01, 3.50)	0.10 (0.01, 1.56)	0.75 (0.03, 21.89)	0.25 (0.02, 3.22)	0.25 (0.02, 3.28)	0.12 (0.01, 2.18)	Linifanib
2.45 (0.21, 26.97)	1.44 (0.16, 11.84)	10.38 (0.55, 183.07)	3.59 (0.48, 23.72)	3.64 (0.49, 23.92)	1.73 (0.16, 16.98)	14.02 (1.23, 151.60)	Placebo
0.34 (0.02, 6.17)	0.20 (0.01, 2.79)	1.43 (0.05, 40.65)	0.49 (0.04, 5.69)	0.50 (0.04, 5.87)	0.24 (0.01, 3.93)	1.94 (0.11, 34.50)	0.14 (0.01, 1.46)	Sintilimab + Bevacizumab
0.70 (0.08, 5.86)	0.41 (0.07, 2.44)	2.99 (0.21, 41.96)	1.01 (0.22, 4.63)	1.02 (0.22, 4.71)	0.49 (0.07, 3.59)	4.02 (0.50, 32.40)	0.28 (0.09, 1.01)	2.06 (0.29, 14.88)	Sorafenib

AEs, adverse events.